Department of Orthopaedic Surgery-A41, Cleveland Clinic, Cleveland, Ohio 44195, USA.
J Arthroplasty. 2012 May;27(5):695-702. doi: 10.1016/j.arth.2011.09.014. Epub 2011 Oct 27.
The purpose of this study was to evaluate the effectiveness of a collagen/thrombin and autologous platelet hemostatic agent in preventing blood loss during primary total knee arthroplasty. This prospective, double-blinded, randomized study was designed to enroll a total of 100 patients. Patients were randomized 1:1 to either the treatment arm (standard hemostasis plus study product) or the control arm (standard hemostasis alone). Transfusion requirements, as determined by a blinded investigator using standardized criteria, were significantly lower in the treatment group (no blood transfusions) compared with the control group (5 transfusions; P = .007). These data support the addition of the study product to prevent blood transfusions after primary total knee arthroplasty.
本研究旨在评估胶原蛋白/凝血酶和自体血小板止血剂在预防初次全膝关节置换术中失血方面的有效性。这是一项前瞻性、双盲、随机研究,计划纳入 100 例患者。患者按 1:1 随机分为治疗组(标准止血+研究产品)或对照组(标准止血)。采用盲法研究者根据标准化标准判断,治疗组的输血需求明显低于对照组(5 例输血;P=0.007)。这些数据支持添加研究产品以预防初次全膝关节置换术后输血。